Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000950142-25-001391
Filing Date
2025-05-15
Accepted
2025-05-15 08:13:34
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 34613
2 SCHEDULE A eh250623393_scha.htm EX-99 7264
3 EXHIBIT 1 eh250623393_ex01.htm EX-99.1 81292
  Complete submission text file 0000950142-25-001391.txt   125188
Mailing Address 55 EAST 52ND STREET 33RD FLOOR NEW YORK NY 10055
Business Address 55 EAST 52ND STREET 33RD FLOOR NEW YORK NY 10055 212 715 4000
GENERAL ATLANTIC, L.P. (Filed by) CIK: 0001017645 (see all company filings)

EIN.: 133503735 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A

Mailing Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080
Business Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 650-487-6488
Akero Therapeutics, Inc. (Subject) CIK: 0001744659 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-91047 | Film No.: 25948859
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)